Redeye comments on Lipum’s announcement of the finalized Clinical Study Report (CSR) for the phase I...
Slightly softer sales and outlook (-5% vs. ABGSCe in Q4) We cut '25e-'26e sales by 9-8%, EBIT 24-15%...
Redeye offers a preview of Polygien's Q1 results set to be released on April 24.
Redeye comments on Carasent’s Q1 report, showing solid ARR growth yet somewhat higher OPEX.
Incap had already anticipated a slow start for 2025, and now the entire EMS sector is holding its br...
Redeye expects Smart Eye’s Q1 report, due May 13, to show 12% y/y net sales growth and an EBITDA imp...
Redeye comments on SenzaGen’s expanded testing portfolio, introducing the EpiSensA method, which com...
Genetic Analysis AS (”Genetic Analysis” or ”the Company”) has developed the GA-map®, a platform for ...
Redeye provides a short comment on the trading update from Cheffelo released earlier this morning.
Q1e: clean EBIT of ~SEK -45m, Q2 likely better Pulp prices up, but futures point down Fair value ran...
Redeye gives its view on mezagitamab, whose phase III start triggered a milestone payment to BioInve...
Redeye sees an interesting opportunity in Transtema, which is trading close to its four-year low des...
Global efterfrågan driver tillväxtmöjligheter LifeClean verkar på en växande marknad där skärpta kra...
Redeye comments on the preliminary one-year results from the ProTrans-Young trial, announced by Next...
Relais announced today that it will acquire a majority stake in Matro Group, a well-established dist...
